UAE Develops a Rapid Coronavirus Laser Testing Technology

Rapid Coronavirus Laser Testing Technology: QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company (IHC), announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale. This break-through will enable ‘Mass-scale screening’, changing the whole dimension of tracing.

AbdulRahman bin Mohammed Al Owais, Minister of Health and Prevention, expressed hope over the discovery saying: “We are always following innovations related to the early and rapid detection of Covid–19. The government is keen on supporting initiatives that help the healthcare system in the UAE. Health officials have been closely monitoring the progress of trials with QuantLase in order to test this equipment. We are proud to see a technology that works and that will help to protect our people better.”

“The equipment, which uses a CMOS detector, will enable mass-scale screening with results made available in seconds,” said Dr Pramod Kumar, who leads the team of researchers at the lab which has been studying the change in cell structure of the virus-infected blood.

“In fact, our laser-based DPI [Diffractive Phase Interferometry] technique, based on optical-phase modulation, is able to give a signature of infection within a few seconds. What’s more, it is user-friendly, non-invasive and low-cost. We believe it will be a game-changer in tackling the spread of the coronavirus.”

Explaining the critical role of artificial intelligence (AI) in the diagnostic system, Dr Kumar said that an advanced AI image-analysis model predicts the outcome of each image with precision, speed and scale. This is especially critical in large-scale testing programs, where a massive number of images needs to be analysed with accuracy and efficiency. The lab is using G42, a leading AI and Cloud Computing company, to further enhance the laser program.

Other featured news.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”